Spanish pharma Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J.

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Shares in Spanish pharma group Grifols have plummeted after UK-based hedge fund Gotham City Research issued a report claiming it has fraudulently manipulated its financial reporting by not ...

Grifols has received a $21 million grant from The Michael J. Fox Foundation to fund a pioneering study aimed at identifying ...

Private equity company Brookfield has reportedly moved closer to taking control of Grifols, after months of disruption at the Spanish pharma company. A report in Spanish newspaper El Confidencial ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF ...

(Bloomberg) -- Drugmaker Grifols SA and US short seller Gotham ... Schools Wrecked by Fires ‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing ...

ADMA Biologics, which competes with Takeda TAK and Grifols GRFS in the market of plasma-derived products in the United States ...

The Biologics License Application (BLA ... ensuring timely and targeted treatment. As a member of the Grifols Group, Biotest is committed to playing a leading role in expanding access to this ...

Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological ...